Treatment of patients with chronic heart failure and reduced left ventricular ejection fraction: is there a light at the end of the tunnel?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Despite the progress that was reached in the treatment of chronic heart failure (CHF), the mortality and the frequency of hospitalizations, remain high. The search for new treatment options for CHF that can improve the prognosis of the disease is still an urgent problem. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors developed for the treatment of type 2 diabetes mellitus have demonstrated improved prognosis in patients with cardiovascular disease (CVD) regardless of the presence or absence of diabetes. This review is devoted to the discussion of modern methods of treatment of heart failure with reduced left ventricular ejection fraction (HFrEF), the status and perspectives for the use of SGLT2 inhibitors in this category of patients. Possible mechanisms of action of SGLT2 inhibitors that prevent the development of cardiovascular complications are considered. Special attention is paid to the analysis of the EMPEROR-Reduced study, which proved the effectiveness of the administration of empagliflozin in addition to standard therapy in patients with HFrEF.

Full Text

Restricted Access

About the authors

Valentin A. Kokorin

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia

Email: valentinkokorin@yahoo.com
MD, PhD, DMSci, associate professor, professor of the Department of hospital therapy named after academician P.E. Lukomsky

Olga I. Boeva

Central State Medical Academy of the Presidential Executive Office

Email: box0271@mail.ru
MD, PhD, DMSci, associate professor, professor of the Department of therapy, cardiology and functional diagnostics with the course of nephrology

References

  1. Savarese G., Lund L.H. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017; 3(1): 7-11. doi: 10.15420/cfr.2016:25:2.
  2. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(27): 2129-200. doi: 10.1093/eurheartj/ehw128.
  3. Хроническая сердечная недостаточность. Клинические рекомендации Министерства здравоохранения РФ. 2020; 112 c. Доступ: https://crprodapi.nitrosbase.com/api.ashx?op=GetClinrecPdf&id=156_1 (дата обращения - 11.05.2021).
  4. Сердечная недостаточность: актуальные вопросы диагностики, лечения и профилактики с позиций доказательной медицины. Междисциплинарное учебное пособие. Под ред. Лариной В.Н. М.: РНИМУ им. Н.И. Пирогова. 2020; 292 с. ISBN: 978-5-88458-506-5.
  5. Мареев В.Ю., Фомин И.В., Агеев Ф.Т. с соавт. Клинические рекомендации ОССН - РКО - РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; S6: 8-158. doi: https://dx.doi.org/10.18087/cardio.2475.
  6. Кобалава Ж.Д., Лазарев П.В., Виллевальде С.В. Ингибиторы SGLT2: обоснование и перспективы применения при сердечной недостаточности. Кардиология. 2018; 2: 42-54. doi: https://dx.doi.org/10.18087/cardio.2018.2.10087.
  7. Wright E.M., Hirsch J.R., Loo D.D., Zampighi G.A. Regulation of Na+/glucose cotransporters. J. Exp Biol. 1997; 200(Pt 2): 287-93.
  8. Adachi T., Yasuda K., Okamoto Y. et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000; 49(8): 990-95. doi: 10.1053/meta.2000.7729.
  9. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl J. Med. 2015; 373(22): 2117-28. doi: 10.1056/NEJMoa1504720.
  10. McGuire D.K., Zinman B., Inzucchi S.E. et al. Effects of empagliflozin on first plus recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: Results from the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020; 8(12): 949-59. doi: 10.1016/S2213-8587(20)30344-2.
  11. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl J. Med. 2017; 377(7): 644-57. doi: 10.1056/NEJMoa1611925.
  12. Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl J. Med. 2019; 380(4): 347-57. doi: 10.1056/NEJMoa1812389.
  13. Хасанов Н.Р. Эффекты применения ингибитора натрий-глюкозного котранспортера 2 типа дапаглифлозина у пациентов с сердечной недостаточностью с низкой фракцией выброса левого желудочка. Российский кардиологический журнал. 2020; 8: 83-90. doi: https://dx.doi.org/10.15829/1560-4071-2020-4049.
  14. Lee M.M.Y., Brooksbank K.J.M., Wetherall K. et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021; 143(6): 516-25. doi: 10.1161/ CIRCULATIONAHA.120.052186.
  15. Лебедева А.Ю., Котешкова О.М., Джиоева О.Н. с соавт. Дополнительные возможности в лечении пациентов с хронической сердечной недостаточностью. От исследования EMPA-REG OUTCOME к исследованию EMPEROR-REDUCED. Резолюция онлайн совещания экспертов Москвы. Рациональная фармакотерапия в кардиологии. 2021; 1: 165-168. doi: https://dx.doi.org/10.20996/1819-6446-2021-01-03.
  16. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl J. Med. 2019; 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303.
  17. Packer M., Butler J., Filippatos G.et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J. Heart Fail. 2019; 21(10): 1270-78. doi: 10.1002/ejhf.1536.
  18. Packer M., Anker S.D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. 2020; 383(15): 1413-24. doi: 10.1056/NEJMoa2022190.
  19. Packer M., Butler J., Anker S.D. et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial. Circulation. 2021; 143(4): 326-36. doi: 10.1161/CIRCULATIONAHA.120.051783.
  20. Anker S.D., Butler J., Filippatos G. et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - results from the EMPEROR-Reduced trial. Circulation. 2021; 143(4): 337-49. doi: 10.1161/ CIRCULATIONAHA.120.051824.
  21. Butler J., Anker S.D., Filippatos G. et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021; 42(13): 1203-12. doi: 10.1093/eurheartj/ehaa1007.
  22. Zannad F., Ferreira J.P., Pocock S.J. et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced trial. Circulation. 2021; 143(4): 310-21. doi: 10.1161/CIRCULATIONAHA.120.051685.
  23. Ferreira J.P., Zannad F., Pocock S.J. et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure EMPEROR-Reduced. J. Am Coll Cardiol. 2021; 77(11): 1397-407. doi: 10.1016/j.jacc.2021.01.044.
  24. Packer M., Anker S.D., Butler J. et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021; 42(6): 671-80. doi: 10.1093/ eurheartj/ehaa968.
  25. Packer M., Anker S.D., Butler J. et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload EMPEROR-Reduced trial. J. Am Coll Cardiol. 2021; 77(11): 1381-92. doi: 10.1016/j.jacc.2021.01.033.
  26. Zannad F., Ferreira J.P., Pocock S.J. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a metaanalysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396(10254): 819-29. doi: 10.1016/S0140-6736(20)31824-9.
  27. Maddox T.M., Januzzi J.L., Allen L.A. et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J. Am Coll Cardiol. 2021; 77(6): 772-810. doi: 10.1016/j.jacc.2020.11.022.
  28. McMurray J.J.V., Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation. 2021; 143(9): 875-77. doi: 10.1161/circulationaha.120.052926.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies